Compare TAYD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | PLX |
|---|---|---|
| Founded | 1955 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 207.1M |
| IPO Year | 1995 | 1996 |
| Metric | TAYD | PLX |
|---|---|---|
| Price | $55.70 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.6K | ★ 836.2K |
| Earning Date | 10-02-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.14 | ★ 0.27 |
| Revenue | $41,649,673.00 | ★ $52,744,000.00 |
| Revenue This Year | $25.09 | $55.77 |
| Revenue Next Year | $23.22 | N/A |
| P/E Ratio | $403.00 | ★ $9.46 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $43.14 | $1.65 |
| 52 Week High | $90.37 | $3.19 |
| Indicator | TAYD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 42.44 |
| Support Level | $51.63 | $2.21 |
| Resistance Level | $59.69 | $2.75 |
| Average True Range (ATR) | 1.89 | 0.10 |
| MACD | -0.20 | -0.02 |
| Stochastic Oscillator | 42.70 | 19.67 |
Taylor Devices Inc is engaged in the design, development, manufacture and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment and structures. The company continues to develop new and technology products. The company manufactures and sells a group of very similar products that have many different applications for customers. These similar products are included in one of nine categories, namely, Seismic Dampers, Fluidicshoks, Crane and Industrial Buffers, Self-Adjusting Shock Absorbers, Liquid Die Springs, Vibration Dampers, Machined Springs, Custom Shock and Vibration Isolators, and Custom Actuators. It has presence in USA, Asia, and Others. Majority of revenue comes from USA.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.